NCT04379310

Brief Summary

Investigators will recruit patients diagnosed with COVID-19 pneumonia between March 11th, 2020 and April 15th, 2020 in emergency, internal medicine and cardiology outpatient clinics, retrospectively and analyze their clinical and demographic features on admission in regard to their medications used for chronic diseases regularly.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2020

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

May 4, 2020

Completed
1 day until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 5, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 7, 2020

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 8, 2020

Completed
Last Updated

June 5, 2020

Status Verified

June 1, 2020

Enrollment Period

4 days

First QC Date

May 4, 2020

Last Update Submit

June 4, 2020

Conditions

Covid-19

Keywords

covid-19 pneumoniamedicationcomorbidity

Outcome Measures

Primary Outcomes (2)

  • extend of lung involvement

    number of segments involved on admission

    1 week

  • oxygen saturation on admission

    hypoxia

    2 week

Study Arms (1)

covid-19 pneumonia

diagnosed with covid-19 by using PCR and computed tomography scans

Drug: ACE Inhibitors and Calcium Channel Blockers

Interventions

ACE Inhibitors and Calcium Channel BlockersDRUG

effect of drugs on patients with covid-19 pneumonia

Also known as: NSAID
covid-19 pneumonia

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

first diagnosis with covid-19 pneumonia

You may qualify if:

  • Covid-19 pneumonia at least with typical infiltration on CT +/- positive PCR.

You may not qualify if:

  • no typical infiltration and negative PCR results.
  • not newly diagnosed.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vital Hospital

Bahçelievler, Istanbul, 34230, Turkey (Türkiye)

Location

MeSH Terms

Conditions

COVID-19

Interventions

Angiotensin-Converting Enzyme InhibitorsCalcium Channel BlockersAnti-Inflammatory Agents, Non-Steroidal

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Protease InhibitorsEnzyme InhibitorsMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesMembrane Transport ModulatorsCalcium-Regulating Hormones and AgentsPhysiological Effects of DrugsCardiovascular AgentsTherapeutic UsesAnalgesics, Non-NarcoticAnalgesicsSensory System AgentsPeripheral Nervous System AgentsAnti-Inflammatory AgentsAntirheumatic Agents

Study Officials

  • Hasan Haciosman

    academic staff, MD

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
M.D.

Study Record Dates

First Submitted

May 4, 2020

First Posted

May 7, 2020

Study Start

May 1, 2020

Primary Completion

May 5, 2020

Study Completion

May 8, 2020

Last Updated

June 5, 2020

Record last verified: 2020-06

Data Sharing

IPD Sharing
Will share

patient characteristics and time interval will be shared

Shared Documents
STUDY PROTOCOL
Time Frame
in two months
Access Criteria
all researchers

Locations

TU(1)